Carnival of Biotechnology

August 16, 2007

Welcome to the second August 2007 edition of Carnival of Biotechnology. International Biotechnology The Times (UK) has a report on the UK biotech sector, calling for consolidation to overcome a lack of capital. The Wall Street Journal has an article on Novartis’ lost patent case in India, where a patent on an improved version of [...]

Read the full article →

Carnival of Biotechnology

August 1, 2007

Welcome to the August 2007 edition of Carnival of Biotechnology. Industry Trends Singapore-based ES Cell International, the company that was poised to lead in stem cell therapeutics, has abandoned its plans for stem cell therapies. Sometimes its hard for a company to live up to the high expectations they engender in their quest for financing. [...]

Read the full article →

Carnival of Biotechnology

June 28, 2007

Welcome to the June 25th 2007 edition of Carnival of Biotechnology. Finance and business development BusinessFund.com has a great post on 25 alternatives to venture capital — too many entrepreneurs assume that venture capital is the de facto way to fund a company, when there are many other avenues they should be exploring. Industry Trends [...]

Read the full article →

Carnival of Biotechnology

May 25, 2007

Welcome to the May 25th 2007 edition of Carnival of Biotechnology. Finance and business development The big news on the web is Google’s investment in 23andMe, described here by the California Biotech Law Blog. International biotech Business Week has an article on The Rush To Test Drugs In China. This is a story with a [...]

Read the full article →

Carnival of Biotechnology

April 11, 2007

Welcome to the April 10, 2007 edition of Carnival of Biotechnology. Finance and business development On Pharma presents a report that tens of thousands of pharma sales reps are suing current and former employers for overtime – $1 billion in settlements could be at stake. H.S. Ayoub presents The Biotech Industry: 30 Years of Failure [...]

Read the full article →

Carnival of Biotechnology

March 27, 2007

The latest Carnival of Biotechnology is up at Baby Biotechs. Great job, Brian! For more information, see the Carnival of Biotechnology Homepage, or submit a link for the next edition. Interested in hosting a future Carnival of Biotechnology? Let me know.

Read the full article →

Carnival of Biotechnology

March 13, 2007

Investing and Clinical Trials PharmaGossip has an illuminating excerpt from The End of Medicine describing a method to invest in drug companies as they progress through clinical trials. Ted Love, CEO of Nuvelo Inc., explains how biotechnology companies are frequently able to recover from seemingly disastrous clinical trial failures. Patents When manufacturers seeking to sell [...]

Read the full article →

Carnival of Biotechnology

February 18, 2007

Scientific Advances The MaRS Blog has a captivating story of Canada’s recent major diabetes discovery. The first discovery, in 1920, elucidated insulin’s central role in diabetes. The most recent discovery, also from the University of Toronto, has found a strong link between diabetes, pain nerves, and inflammation. Researchers were able to prevent and even reverse [...]

Read the full article →

Carnival of Biotechnology

January 28, 2007

This edition of the Carnival of Biotechnology features a number of posts on distressing industry trends, some enlightening patent discussion, and interesting commentary on issues in commercialization Industry Trends Forbes presents Genentech’s Next Act. his dialogue with Genentech’s chief officers acknowledges the longshot Genentech was in its early days and plots the future paths Genentech [...]

Read the full article →

Carnival of Biotechnology

December 9, 2006

Lots of interesting developments since the last edition: Pfizer’s high-profile drug failiure, a new law against violent extremists, good news for Merck, and good and bad news for the biotechnology industry as a whole. News and Trends The Washington Times has an update on the signing of the Animal Enterprise Terrorism Act. Bolstered by recent [...]

Read the full article →

← Previous Entries